Evidence map›Paper›PMID 31384086›Full record

ArticleSudanese journal of paediatrics2019

Lactulose versus polyethylene glycol for disimpaction therapy in constipated children, a randomized controlled study.

Mohammad Salem Shatnawi, Mohammad Mu'azi Alrwalah, Abdulla Majed Ghanma, Mohammad Lutfi Alqura'an, Ehab Nequla Zreiqat, Manar Mohammad Alzu'bi

Registry-linked trialAbstract read
In one paragraph

Article in Sudanese journal of paediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06349031 (Comparison of Efficacy & Tolerability Of Polyethylene Glycol 4000 Versus Polyethylene Glycol 3350+ Electrolytes For Fecal Disimpaction in Pediatric Functional Constipation), which is not on this map. Cited by 8 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 3 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06349031 phase4unknown statusnot on this mapstarted 2024, after this paper: background citation

Comparison of Efficacy & Tolerability Of Polyethylene Glycol 4000 Versus Polyethylene Glycol 3350+ Electrolytes For Fecal Disimpaction in Pediatric Functional Constipation: A Double-Blind Randomized Controlled Trial

TypeinterventionalSponsorInstitute of Medical Sciences and SUM HospitalRan2024 to 2024Enrolled100ConditionsFunctional Constipation, Fecal Impaction, Constipation - Functional, Constipation Chronic IdiopathicArmsAdministration of Polyethylene Glycol (PEG) 4000 as per treatment allocation to participants, Administration of Polyethylene Glycol (PEG) 3350 + Electrolyte as per treatment allocation to participants
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 3 syntheses or guidelines pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Review
  7. Review
  8. Roles of Gut Microbiota and Metabolites in Pathogenesis of Functional Constipation.Evidence-based complementary and alternative medicine : eCAM · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mohammad Salem ShatnawiLieutenant Colonel, Senior Pediatric Gastroenterologist, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Royal Medical Services, Amman, Jordan.
Mohammad Mu'azi AlrwalahLieutenant Colonel, Senior Pediatric Gastroenterologist, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Royal Medical Services, Amman, Jordan.
Abdulla Majed GhanmaBrigadier, Head of Pediatric Gastroenterology Department, Consultant Pediatric Gastroenterologist, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Royal Medical Services, Amman, Jordan.
Mohammad Lutfi Alqura'anMajor, Pediatric Gastroenterologist, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Royal Medical Services, Amman, Jordan.
Ehab Nequla ZreiqatMajor, Pediatric Gastroenterologist, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Royal Medical Services, Amman, Jordan.
Manar Mohammad Alzu'biPediatric Gastroenterologist, Department of Pediatric Gastroenterology, Hepatology and Nutrition, Royal Medical Services, Amman, Jordan.
King Hussein Medical Center · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Faecal disimpaction is very important for successful management of the constipation in children. Lactulose is cheap and widely available medicine compared to other polyethylene glycol (PEG) preparations. From our experience, lactulose is effective and safe medicine for both disimpaction and maintenance therapy in constipated children. The purpose of the present study was to evaluate the safety and efficacy of lactulose in faecal impaction management in children with constipation. We conducted a prospective controlled trial in children with functional constipation, who presented with faecal impaction to Queen Rania Hospital for Children from April 15, 2018 until October 15, 2018. Two randomised matched groups; group A included 33 constipated children treated for disimpaction with higher dose lactulose (10 g/15 ml) 4-6 ml/kg/day (max. 120 ml/day) and group B included 32 children treated for disimpaction with macrogol (PEG 4000) 1-1.5 g/kg (max. 30 g/day). Both groups received treatment until resolution or up to 6 days. Patients were followed over 1 week and success of disimpaction was observed. Moreover, any adverse events were recorded. All the patients in both groups achieved successful disimpaction by seventh day of the therapy, group B showed significant faster response. Both therapies were tolerated and no significant adverse events were reported. Both agents were safe, effective and well tolerated. Lactulose may be a good alternative to PEG in the treatment of faecal impaction in constipated children.

Indexed as

ChildrenConstipationDisimpactionLactulose

Identifiers

PMID31384086
PMCPMC6589805
OpenAlexW2962934229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.